These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 24825735)

  • 1. Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial.
    Takeshima N; Matoda M; Abe M; Hirashima Y; Kai K; Nasu K; Takano M; Furuya K; Sato S; Itamochi H; Tsubamoto H; Hasegawa K; Terao K; Otsuki T; Kuritani K; Ito K
    Support Care Cancer; 2014 Nov; 22(11):2891-8. PubMed ID: 24825735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
    Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
    Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T
    Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
    Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
    Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
    Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.
    Hamada S; Hinotsu S; Kawai K; Yamada S; Narita S; Kamba T; Nishiyama H; Arai Y; Habuchi T; Ogawa O; Kawakami K
    Support Care Cancer; 2014 Aug; 22(8):2161-6. PubMed ID: 24652048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting.
    Hesketh PJ; Sanz-Altamira P
    Support Care Cancer; 2012 Mar; 20(3):653-6. PubMed ID: 22089429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy.
    Kitazaki T; Fukuda Y; Fukahori S; Oyanagi K; Soda H; Nakamura Y; Kohno S
    Support Care Cancer; 2015 Jan; 23(1):185-90. PubMed ID: 25063271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
    Nakashima K; Murakami H; Yokoyama K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Nishiyama F; Kikugawa M; Kaneko M; Iwamoto Y; Koizumi S; Mori K; Isobe T; Takahashi T
    Jpn J Clin Oncol; 2017 Sep; 47(9):840-843. PubMed ID: 28633504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
    Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
    Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
    Miura S; Watanabe S; Sato K; Makino M; Kobayashi O; Miyao H; Iwashima A; Okajima M; Tanaka J; Tanaka H; Kagamu H; Yokoyama A; Narita I; Yoshizawa H
    Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
    Shi Q; Li W; Li H; Le Q; Liu S; Zong S; Zheng L; Hou F
    Oncotarget; 2016 Apr; 7(17):24402-14. PubMed ID: 27015550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
    Yang CK; Wu CE; Liaw CC
    Biomed J; 2016 Feb; 39(1):60-6. PubMed ID: 27105599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy.
    Lorusso V; Giampaglia M; Petrucelli L; Saracino V; Perrone T; Gnoni A
    Support Care Cancer; 2012 Dec; 20(12):3241-6. PubMed ID: 22534864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K; Fushida S; Kaji M; Takeda T; Kinami S; Hirono Y; Yoshimoto K; Yabushita K; Hirosawa H; Takai Y; Nakano T; Kimura H; Yasui T; Tsuneda A; Tsukada T; Kinoshita J; Fujimura T; Ohta T
    J Gastroenterol; 2013 Nov; 48(11):1234-41. PubMed ID: 23338487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer.
    Wu F; Lin X; Yang Z; Sun Z; Zeng F; Heng J; Qu J; Zeng L; Yang N; Zhang Y
    Clin Lung Cancer; 2018 Nov; 19(6):e913-e918. PubMed ID: 30197265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
    Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
    Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.